ReviewFrontiers in medicine2025
Rsearch progress on the relationship between aging and microbiota in sarcopenia.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated bioinformatics and mendelian randomization reveal a six-gene diagnostic signature and key role of CYP26B1 in sarcopenia.Frontiers in molecular biosciences · 2026Article
- Exploring the intricate link between gut microbiota dysbiosis and the aging process: implications for age-related diseases.Gut pathogens · 2025Review
- The relationships between Life's Crucial 9, Life's Essential 8, and sarcopenia in older adults: multicenter case-control study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is an age-related skeletal muscle disease associated with adverse outcomes such as falls, decreased function, frailty, and death, and is a significant global public health problem that impairs the functioning of individuals. Aging is intensifying, the number of people with sarcopenia is increasing, and there are currently no specific treatment drugs for sarcopenia. The clinical pathogenesis of sarcopenia is extremely complex, and the underlying mechanism of immunosenescence and dysbiosis associated with aging on sarcopenia is not well studied, and they are also potential therapeutic targets for sarcopenia. This review mainly discusses the relationship between sarcopenia from the perspective of intestinal microbiota dysbiosis and T cell changes in immunosenescence, and looks for promising targets for diagnosis or intervention of sarcopenia in the future, hoping to achieve early detection, early diagnosis and early treatment of sarcopenia and prolong the life span of healthy aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.